{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:35:28Z","timestamp":1789850128715,"version":"4.0.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s13730-021-00601-1","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T16:31:08Z","timestamp":1619454668000},"page":"523-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-5464","authenticated-orcid":false,"given":"Mari","family":"Saimiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manao","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"601_CR1","first-page":"51","volume":"3","author":"S Nodari","year":"2010","unstructured":"Nodari S, Jao GT, Chiong JR. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients. Int J Nephrol Renovasc Dis. 2010;3:51\u201360.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"601_CR2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319\u201331.","journal-title":"JAMA"},{"key":"601_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/hepr.12098","volume":"44","author":"I Sakaida","year":"2014","unstructured":"Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K, Okada M, Okita K. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73\u201382.","journal-title":"Hepatol Res"},{"key":"601_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1536\/ihj.13-221","volume":"55","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Komuro I. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J. 2014;55:131\u20137.","journal-title":"Int Heart J"},{"key":"601_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00467-013-2687-1","volume":"29","author":"M Shimizu","year":"2014","unstructured":"Shimizu M, Ishikawa S, Yachi Y, Muraoka M, Tasaki Y, Iwasaki H, Kuroda M, Ohta K, Yachie A. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. Pediatr Nephrol. 2014;29:915\u20137.","journal-title":"Pediatr Nephrol"},{"key":"601_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/ijn.IJN_358_18","volume":"30","author":"J Meena","year":"2020","unstructured":"Meena J, Sinha A, Hari P, Bagga A. Therapy with the combination of tolvaptan and furosemide for refractory edema in nephrotic syndrome. Indian J Nephrol. 2020;30:53\u20135.","journal-title":"Indian J Nephrol"},{"key":"601_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/ki.1984.34","volume":"25","author":"M Usberti","year":"1984","unstructured":"Usberti M, Federico S, Meccariello S, Cianciaruso B, Balletta M, Pecoraro C, Sacca L, Ungaro B, Pisanti N, Andreucci VE. Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome. Kidney Int. 1984;25:422\u20139.","journal-title":"Kidney Int"},{"key":"601_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2215\/CJN.04390808","volume":"4","author":"G Kapur","year":"2009","unstructured":"Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone-a prospective study. Clin J Am Soc Nephrol. 2009;4:907\u201313.","journal-title":"Clin J Am Soc Nephrol"},{"key":"601_CR9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00467-020-04530-6","volume":"35","author":"JD Delbet","year":"2020","unstructured":"Delbet JD, Parmentier C, Ulinski T. Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome. Pediatr Nephrol. 2020;35:1347\u201350.","journal-title":"Pediatr Nephrol"},{"key":"601_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patient -association between non-responders and chronic kidney disease. Circ J. 2013;77:397\u2013404.","journal-title":"Circ J"},{"key":"601_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/ki.2013.350","volume":"85","author":"SE Shoaf","year":"2014","unstructured":"Shoaf SE, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 2014;85:953\u201361.","journal-title":"Kidney Int"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-021-00601-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T09:36:00Z","timestamp":1633599360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-021-00601-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1007\/s13730-021-00601-1","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"4 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has a direct conflict of interest that is relevant to this study. Outside the contents of the study, Yoshitsugu Kaku received travel fees from CLS Behring.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}